CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

Baird Downgrades Medpace to Neutral From Outperform, Adjusts PT to $547 From $477

Negative
AI Analysis

Summary

Baird downgraded Medpace from Outperform to Neutral and reduced price target from $477 to $547.

Importance:3/10
Sentiment:
-0.50
analyst_downgradeprice_target_adjustment
Related Companies

Read the original article

Published by yahoo_finance on July 8, 2026 12:00 PM

Read Original